Skip to content
Monday, 16 November 2026
Inspire.News

Unveiling truth, one story at a time

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
Image: South China Morning Post

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit…

Full story

Continue reading this story on South China Morning Post, the publisher that reported it.

Read the full story at South China Morning Post ↗

AI tools

Written by AI from the article text. It can make mistakes; check the original story.

Topics in this story

More from Business · Asian

See all